Insilico Medicine is a globally leading end-to-end generative AI-driven biotech company in terms of AIDD pipeline progress, with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary Pharma.AI platform across biology, chemistry and clinical development.
Insilico Medicine's generative AI platform helps them to rapidly and efficiently advance our fully self-generated AIDD pipeline primarily composed of novel drug candidates.
With strong business development abilities, Insilico Medicine has received strong external validation of the company's platform with collaborations with leading industry partners around the globe, including 10 of the top 20 global pharmaceutical companies in terms of 2021 reported sales, and established collaboration with top institutions, universities, and industry leaders on the company's core AI projects.
Insilico Medicine has enjoyed long-term support from globally leading financial and strategic investors in technology, healthcare and AI industries, including Warburg Pincus, Qiming Venture Partners, Wuxi AppTec, B Capital Group, Prosperity 7, OrbiMed, Deerfield, Pavilion Capital, PIDC, CPE fund, Mirae Asset Capital, Lilly Asia Ventures, Eight Roads, Lake Bleu Capital, Baidu Ventures and Sinovation Ventures.
Insilico Medicine Documentary: A breakthrough milestone in AI-powered drug discovery reached